Suppr超能文献

基于直线加速器的立体定向体部放射治疗低中危前列腺癌的 II 期临床试验的长期毒性和生存更新。

Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.

机构信息

Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

出版信息

Prostate. 2024 Mar;84(4):368-375. doi: 10.1002/pros.24657. Epub 2023 Dec 19.

Abstract

BACKGROUND

In 2016 we published a phase II study exploring safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) delivered with Volumetric Modulated Arc Therapy (VMAT) and Flattening Filter Free (FFF) beams techniques in prostate cancer (PC) patients. We present herein the updated results on late toxicity and long-term survival.

METHODS

Patients enrolled in the study had a biopsy-confirmed localized PC and the features of a low- or intermediate-risk disease (National Comprehensive Network Criteria). The radiotherapy (RT) schedule consisted of 35 Gy delivered in five fractions every other day. Toxicities were registered according to the common toxicity adverse events v4.0. Biochemical recurrence was defined as an increase of prostate specific antigen after nadir, confirmed at least once. Local recurrence (LR) and distant metastases were detected either with Choline- or PSMA-PET/CT scans. Kaplan-Meier curves for Biochemical Recurrence-Free Survival (BFS), Local Control (LC), Distant Metastasis Free Survival (DMFS) and Cancer Specific Survival, were calculated by using MedCalc.

RESULTS

Ninety patients were submitted to SBRT between February 2012 and March 2015. Fifty-eight patients (64.5%) had a Gleason Score of 6, while 32 (35.5%) had a Gleason Score of 7. A late grade 1 Genito-Urinary toxicity was observed in 54.5% of patients while a grade 2 in 3.3%. A late Gastro-intestinal grade 1 toxicity was reported in 18.9% of patients, while a grade 2 in 2.2%. Erectile dysfunction was reported by 13% of patients No heavier toxicities were observed. At a median follow-up of 102 months, 5- and 8-year BFS were 93.0% and 84.4% respectively, 5- and 8-year LC were 95.2% and 87.0% respectively, 5- and 8-year DMFS were 95.3% and 88.4%, respectively.

CONCLUSIONS

This long-term update confirms that SBRT is a valid therapeutic strategy for low-intermediate risk PC. RT with VMAT and FFF warrants optimal results in terms of toxicity and disease control.

摘要

背景

2016 年,我们发表了一项 II 期研究,探讨了容积旋转调强放疗(VMAT)联合适形调强放疗(FFF)技术在前列腺癌(PC)患者中的安全性和疗效。我们在此介绍晚期毒性和长期生存的最新结果。

方法

入组患者为经活检证实的局限性 PC 患者,且具有低危或中危疾病特征(国家综合网络标准)。放疗(RT)方案包括 35Gy,每天两次,分 5 次给予。毒性根据通用毒性不良事件 v4.0 进行登记。生化复发定义为 PSA 最低点后升高,至少确认一次。局部复发(LR)和远处转移通过胆碱或 PSMA-PET/CT 扫描检测。采用 MedCalc 计算生化无复发生存(BFS)、局部控制(LC)、远处无转移生存(DMFS)和癌症特异性生存的 Kaplan-Meier 曲线。

结果

2012 年 2 月至 2015 年 3 月,90 例患者接受 SBRT。58 例(64.5%)患者 Gleason 评分为 6,32 例(35.5%)患者 Gleason 评分为 7。54.5%的患者出现晚期 1 级泌尿生殖系统毒性,3.3%的患者出现 2 级毒性。18.9%的患者出现晚期 1 级胃肠道毒性,2.2%的患者出现 2 级毒性。13%的患者报告出现勃起功能障碍。未观察到更严重的毒性。中位随访 102 个月后,5 年和 8 年 BFS 分别为 93.0%和 84.4%,5 年和 8 年 LC 分别为 95.2%和 87.0%,5 年和 8 年 DMFS 分别为 95.3%和 88.4%。

结论

这项长期更新证实,SBRT 是低危中危 PC 的有效治疗策略。VMAT 和 FFF 的 RT 在毒性和疾病控制方面可获得最佳结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验